Latest Apra Regulation News

Challenger has used its 2026 AGM to showcase stronger earnings, record annuity sales and a substantial capital buffer while keeping discussions open with TAL Daiichi Life over its $11.80-per-share approach. The board still does not consider the proposal sufficient to recommend to shareholders.

NobleOak Life Limited boosted its Embedded Value by 9% to $2.34 per share as of December 2025, driven by strong premium growth and market share gains. The insurer exceeded its FY26 in-force premium guidance with a 16% increase to $538 million.

VanEck Investments Limited has released a comprehensive Product Disclosure Statement for seven Australian bond ETFs, detailing investment strategies, risks, fees, and operational frameworks under ASX AQUA Rules.

QBE Insurance Group has priced a $300 million issue of USD subordinated notes due in 2037, offering investors a fixed 5.239% interest rate initially, with a reset in 2032 tied to U.S. Treasury yields. These notes strengthen QBE’s regulatory capital under APRA’s framework.

TAL Dai-ichi Life Australia has obtained all necessary regulatory approvals, including from APRA, to finalize its minority investment in Challenger Limited, acquiring a 19.9% equity stake.

QBE Insurance Group has priced a AUD 600 million subordinated notes issuance, strengthening its capital base under APRA regulations with notes maturing in 2036.

Bendigo and Adelaide Bank has released its Basel III Pillar 3 disclosures for the year ended December 31, 2024, revealing solid capital adequacy and liquidity positions under APRA regulations. The bank maintains robust buffers amid lending growth and evolving market conditions.